Company intelligence / Profile preview

ARISTA Biotech

Ownership: Private
Development stage: Commercial

Overview

ARISTA Biotech provides innovative and affordable COVID‑19 diagnostic products, notably the ARISTA™ COVID‑19 Antigen Rapid Test, which detects all major SARS-CoV‑2 variants including Omicron sub-lineages BA.4/BA.5 and Delta B.1.617.2. Their products are compatible with digital health management tools like the Viva Life App for record keeping and enterprise safety programs.

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

ARISTA COVID-19 Antigen Rapid Test

Commercial

Indications: COVID-19

Partnerships

No specific partnerships disclosed; integration with Viva Life App/Viva Life Enterprise Account for digital health management.

Beyond the preview

Go deeper on ARISTA Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARISTA Biotech.

Explore the full profile